
Bavencio (avelumab), Merck KGaA and Pfizer’s human anti-programmed death ligand-1 (PD-L1) antibody, combined with the latter’s Inlyta (axitinib) has shown …

Bristol-Myers Squibb has unveiled new Phase 2 data for its investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor, known as …

Public Health England has revealed that an enhanced, “adjuvanted” vaccine is to be made available for over-65s this winter, and …

British Health Secretary Matt Hancock has said that pharmaceutical companies are trying to “rip off taxpayers” and that big business …

Protesters in Manchester have called on the National Institute of Health and Care Excellence (NICE), to overturn their rejection of …

A new report from Public Health England (PHE) has illuminated the primary health concerns in UK society today, revealing the …

Alcon, the eyecare unit of Novartis, is set to move to a new home next year, after its parent company …

The American pharmaceutical industry trade lobby PhRMA has suggested that hospitals are to blame for high drug prices as the …

The billionaire Sackler family, the owners of OxyContin drugmaker Purdue Pharma, have been revealed to own a second opioid drug …

Danish multinational Novo Nordisk has announced that they are increasing their stocks of insulin products to ensure that there are …

What does Brexit mean for drug safety in Europe and the United Kingdom? Louis Goss looks into Britain’s exit from …

Bristol-Myers Squibb has failed to convince NICE to approve the use of its PD-1 inhibitor immunotherapy Opdivo (nivolumab) as an …

Keytruda (pembrolizumab) has chalked up yet another approval for MSD, this time in Europe in combination with permextred and platinum-based …

GlaxoSmithKline has suffered a regulatory blow in the label expansion of its interleukin-5 (IL5) inhibitor Nucala (mepolizumab), with the FDA …

Akcea Therapeutics has been hit hard by the FDA’s decision to reject its drug Waylivra (volanesorsen) for the treatment of …

Of the 100,000 MS patients in England, around one in eight have the primary progressive form (PPMS), which brings debilitating …

The UK Government has lifted the curtain on plans invest more than £200 million to leverage innovations in technology and …

Brexit took the top two spots this week after it was revealed that the EMA has awarded Britain’s MHRA just …

The British Columbia Liberal opposition Critic for Mental Health and Addictions has tweeted that the lawsuits seeking damages from pharmaceutical …

Gilead and Galapagos have announced that their jointly-developed selective JAK1 inhibitor filgotinib has met its primary endpoint in a Phase …